文献速递炎症性肠病胰腺与胆道疾病消化道肿瘤与早癌

炎症性肠病与胰腺癌:1969-2017年斯堪的纳维亚登记队列研究

Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017.
PubMed 文献 · Aliment Pharmacol Ther · 2020-05-15

该研究基于丹麦和瑞典国家患者登记及活检数据,纳入1969-2017年新发IBD患者161 926例,并按性别、年龄、居住地和诊断年份匹配无IBD参照个体1 599 024例。结果显示IBD患者胰腺癌风险总体升高(HR 1.43,95%CI 1.30-1.58),合并原发性硬化性胆管炎者风险尤为突出(HR 7.55,95%CI 4.94-11.5),但20年累积发病率绝对差值仅0.05%。

要点

  • IBD患者胰腺癌风险总体升高,HR 1.43(95%CI 1.30-1.58)。
  • 合并原发性硬化性胆管炎者胰腺癌风险显著升高,HR 7.55(95%CI 4.94-11.5)。
  • 20年累积发病率绝对差值仅0.05%,即每2000例IBD患者约多1例胰腺癌。

核心结论

  • IBD患者胰腺癌风险较一般人群升高,尤其合并原发性硬化性胆管炎者。
  • 但20年累积发病率绝对差值小,为0.05%,即每2000例IBD患者约多1例胰腺癌。

研究设计与样本

  • 基于丹麦和瑞典国家患者登记及活检数据,纳入1969-2017年新发IBD患者161 926例。
  • 按性别、年龄、居住地和IBD诊断年份匹配无IBD参照个体1 599 024例。
  • 链接癌症和死因登记,分析胰腺癌及胰腺癌死亡的绝对和相对风险。

主要发现

  • IBD患者中442例(0.27%)诊断胰腺癌,参照个体中3386例(0.21%)。
  • 20年累积发病率IBD患者0.34%(95%CI 0.30-0.38),参照个体0.29%(95%CI 0.28-0.30)。
  • 胰腺癌发病率IBD患者22.1(95%CI 20.1-24.2)/10万人年,参照个体16.6(95%CI 16.0-17.2)/10万人年。
  • 胰腺癌风险总体HR 1.43(95%CI 1.30-1.58);克罗恩病HR 1.44(95%CI 1.18-1.74),溃疡性结肠炎HR 1.35(95%CI 1.19-1.53),未分类IBD HR 1.99(95%CI 1.50-2.64)。
  • 合并原发性硬化性胆管炎的IBD患者HR 7.55(95%CI 4.94-11.5);胰腺癌分期(P=0.17)和胰腺癌死亡(HR 1.07,95%CI 0.95-1.21)在IBD患者与参照个体间无差异。

临床怎么用

  • 对IBD患者,尤其合并原发性硬化性胆管炎者,应关注胰腺癌风险。
  • 鉴于20年绝对风险差值仅0.05%,常规胰腺癌筛查的价值需结合个体风险综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with inflammatory bowel disease (IBD) have an increased risk of cancer. AIM: To assess the risk of pancreatic cancer in IBD compared to the general population. METHODS: Patients with incident IBD 1969-2017 were identified in Danish and Swedish National Patient Registers and through biopsy data, and were matched to IBD-free reference individuals by sex, age, place of residence and year of IBD diagnosis. We linked data to Cancer and Causes of Death Registers and examined the absolute and relative risks of pancreatic cancer and pancreatic cancer death. RESULTS: Among 161 926 patients followed for 2 000 951 person years, 442 (0.27%) were diagnosed with pancreatic cancer compared to 3386 (0.21%) of the 1 599 024 reference individuals. The 20-year cumulative incidence was 0.34% (95% confidence interval 0.30-0.38) vs 0.29% (0.28-0.30). The incidence rate was 22.1 (20.1-24.2)/100 000 person years in the patients (excluding the first year of follow-up: 20.8 [18.8-23.0]), and 16.6 (16.0-17.2) in the reference individuals. The hazard ratio (HR) for pancreatic cancer was increased overall: 1.43 (1.30-1.58), in subtypes (Crohn's disease: 1.44 [1.18-1.74]; ulcerative colitis: 1.35 [1.19-1.53]; IBD unclassified: 1.99 [1.50-2.64]) and especially in IBD patients with primary sclerosing cholangitis: 7.55 (4.94-11.5). Patients and reference individuals with pancreatic cancer did not differ in cancer stage (P = 0.17) or pancreatic cancer mortality (HR 1.07 [0.95-1.21]). CONCLUSIONS: Patients with IBD had an excess risk of pancreatic cancer, in particular patients with primary sclerosing cholangitis. However, the cumulative incidence difference after 20 years was small: 0.05%, that is, one extra pancreatic cancer per 2000 IBD patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Everhov ÅH, Erichsen R, Sachs MC, et al. Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017. Aliment Pharmacol Ther. 2020. PMID: 32412143. doi:10.1111/apt.15785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。